Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know

Core Viewpoint - Adma Biologics has shown strong stock performance recently, with a +17.7% return over the past month, contrasting with the S&P 500's -0.7% change, indicating potential investor interest and market momentum [2]. Earnings Estimate Revisions - The consensus earnings estimate for Adma Biologics is $0.16 per share for the current quarter, reflecting a year-over-year increase of +100% [5]. - For the current fiscal year, the consensus earnings estimate stands at $0.71, indicating a year-over-year change of +44.9% [5]. - The next fiscal year's consensus earnings estimate is $0.93, representing a +31% change from the previous year [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), suggesting a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, indicating a year-over-year increase of +45.5% [11]. - For the current fiscal year, the sales estimate is $495.8 million, reflecting a +16.3% change, while the next fiscal year's estimate is $611.5 million, indicating a +23.3% change [11]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics generated revenues of $117.55 million, a year-over-year increase of +59.1% [12]. - The EPS for the same period was $0.14, compared to $0.04 a year ago, with a revenue surprise of +4.77% against the Zacks Consensus Estimate [12]. - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates each time [13]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17].